Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The authors reported a possible association between the use of etanercept and the development of trichorrhexis nodosa, a hair shaft disorder, in a patient without apparent external causes.

This article reviews TNF-α inhibitor-induced alopecia, identifying various types of hair loss such as severe alopecia areata and scarring alopecia, and calls for more controlled studies to better understand this adverse effect.

This case report describes a 42-year-old woman with rheumatoid arthritis who developed extensive impetiginized pityriasis amiantacea potentially linked to her anti-TNF-α therapy with golimumab. Discontinuing the drug and other treatments led to significant clinical improvement within a month.

Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.

In a retrospective study, TNFα inhibitor-induced alopecia was observed in pediatric patients, primarily adolescents with inflammatory bowel diseases, with hair regrowth occurring in those who discontinued the therapy; this suggests that stopping these medications can improve drug-induced alopecia in children.